| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (NASDAQ:GV), today announced the signing of a strategic cooperation agreement with Jiangsu Yike Regenerative Medical Technology Co., Ltd. ("Yike") to jointly establish Visionary Yike Stemcell Technologies Inc., a Canada-based joint venture dedicated to advancing stem cell research, clinical application, and commercialization worldwide.
Under the agreement, GV and Yike will leverage their respective strengths in global commercialization and regenerative medicine with the goal of advancing the development of stem cell manufacturing and R&D hub in North America. GV's property complex at 95–105 Moatfield Drive, Toronto, Ontario (former IBM headquarters), which comprises more than 40,000 square meters of space, is being considered as the intended headquarters for the joint venture. The parties are assessing the feasibility of developing cleanrooms, low-temperature biostorage, and related infrastructures that could support future cell resource and production operations.
The joint venture will initially focus on stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics and intervention models, leveraging Yike's proprietary platform and GV's global market infrastructure. Both parties will contribute resources and share potential benefits in proportion to their equity stakes, with GV holding 85% and Yike holding 15%. In particular, the joint venture intend to advance the clinical application and commercialization of Yike's breakthrough stem cell technologyincluding both Type 1 and Type 2 diabetes, which has shown early scientific promise in preclinical and exploratory studies.
Through this collaboration, the parties plan to create a vertically integrated regenerative medicine enterprise encompassing R&D, trials, manufacturing, and global sales, which could enhance GV's long-term positioning in the North American stem cell sector.
Posted In: GV
